Lixisenatide

GLP-1 Receptor Agonist — ALIMENTARY TRACT AND METABOLISM

Key facts

Lixisenatide is a drug in the GLP-1 Receptor Agonist class catalogued in DrugCentral. It was first approved by the EMA in 2013. Its mechanism of action is classified as Glucagon-like Peptide-1 (GLP-1) Agonists. DrugCentral lists 1 molecular target, including GLP1R. Recorded indications include Diabetes mellitus type 2.

• Drug class: GLP-1 Receptor Agonist.
• Mechanism of action: Glucagon-like Peptide-1 (GLP-1) Agonists.
• Molecular targets: GLP1R (1 listed in DrugCentral).
• Indications: Diabetes mellitus type 2.
• ATC code: A10AE54 (Insulins and analogues for injection, long-acting).
• Molecular formula: C215H347N61O65S; molecular weight 4858.56 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Diabetes mellitus type 2

Mechanism & targets

• Mechanism of action (MoA): Glucagon-like Peptide-1 (GLP-1) Agonists
• Established pharmacologic class: GLP-1 Receptor Agonist

Molecular targets (1)

Target	Gene	Action	Activity
Glucagon-like peptide 1 receptor	GLP1R	agonist	IC50 8.85

Regulatory approvals (3)

Date	Agency	Marketed as	Applicant	Orphan
2016-07-27	FDA	—	SANOFI-AVENTIS US LLC
2013-05-24	PMDA	—	Sanofi K.K.
2013-02-01	EMA	—	Sanofi-Aventis Groupe

ATC classification

ATC code	Therapeutic hierarchy
A10AE54	ALIMENTARY TRACT AND METABOLISM › DRUGS USED IN DIABETES › INSULINS AND ANALOGUES › Insulins and analogues for injection, long-acting
A10BJ03	ALIMENTARY TRACT AND METABOLISM › DRUGS USED IN DIABETES › BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS › Glucagon-like peptide-1 (GLP-1) analogues

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Diabetic ketoacidosis	61.8

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Lixisenatide is on its molecule page.

• Molecular formula: C₂₁₅H₃₄₇N₆₁O₆₅S
• Molecular weight: 4858.56 g/mol
• CAS number: 320367-13-3
• InChIKey: XVVOERDUTLJJHN-IAEQDCLQSA-N
• PubChem CID: 90472060

CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Lixisenatide used for?

DrugCentral lists the following indications for Lixisenatide: Diabetes mellitus type 2.

How does Lixisenatide work?

Lixisenatide is classified as Glucagon-like Peptide-1 (GLP-1) Agonists; its molecular targets in DrugCentral include GLP1R (agonist).

When was Lixisenatide first approved?

Lixisenatide was first approved by the EMA in 2013.

What drug class does Lixisenatide belong to?

Lixisenatide is in the GLP-1 Receptor Agonist class.

What is the chemical formula of Lixisenatide?

Lixisenatide has the molecular formula C215H347N61O65S and a molecular weight of 4858.56 g/mol.

Sources

• DrugCentral drug card 4815 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL2108336 — compound record and bioactivity
• PubChem CID 90472060 — chemical identifiers
• DrugBank DB09265 — drug record
• FDA UNII 74O62BB01U — substance identity
• DailyMed: FDA labels for Lixisenatide — current prescribing information (label search)
• UniProt P43220 (GLP1R) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.